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Accuracy of injection and short-term pain
relief following intra-articular corticosteroid
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Abstract
Background: Intra-articular corticosteroid injections (IACI) are effective treatments for pain in knee osteoarthritis
(KOA) but treatment response varies. There is uncertainty as to whether structural factors such as accurate placement
of IACI affect outcome. We examined this question in a pragmatic observational study, using ultrasound (US) to verify
accuracy of IACI.
Methods: 105 subjects with KOA (mean age 63.1 years, 59% female) routinely referred for IACI underwent assessment
of demographic factors, x-ray and US of the knee before aspiration and IACI (based on clinical landmarks) with 40 mg
triamcinolone acetonide with lignocaine plus a small amount of atmospheric air by an independent physician. US
demonstration of intra-articular mobile air, i.e. a positive air arthrosonogram, was used to determine accurate placement
of injection. Both patients and injecting physicians were blind to the US findings. Pain at baseline, three and nine weeks
post injection was assessed using the 500 mm WOMAC pain subscale and response defined as≥ 40% reduction in pain
from baseline. Inter-observer reliability of air-arthrosonogram assessment was good: κ 0.79 (three raters).
Results: Sixty-three subjects (60.6%) were responders at three weeks and 43 (45.7%) at nine weeks. Seventy-four subjects
(70.5%) had a positive arthrosonogram. A positive air arthrosonogram did not associate with a higher rate of response to
treatment (p 0.389 at three weeks, p 0.365 at nine weeks). There was no difference in US effusion depth, power Doppler
signal or radiographic grade between responders and non-responders to the injection, but female gender associated
with response at 3 weeks and previous injection with non-response at 9 weeks.
Conclusions: Accurate intra-articular injection of corticosteroid results did not result in superior outcome in terms of pain
compared to inaccurate injection in symptomatic knee OA.
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Background
Osteoarthritis (OA) is the most common form of
arthritis worldwide and its prevalence is increasing [1].
Knee osteoarthritis is one of the most common and
disabling forms of the condition and has significant
clinical and public health impact [2]. In conjunction with
other conservative measures to treat pain in knee OA,
intra-articular corticosteroid injections (IACI) are
commonly used in accordance with published guidance
[3, 4]. Meta-analyses of placebo-controlled studies have
confirmed that IACI provide effective pain relief for at
least three weeks [5, 6], with some studies suggesting
effects of 14 weeks or longer [6]. There is considerable
variation between individuals in both the magnitude and
duration of response and identifying predictors of
response to treatment has been suggested a priority for
research in the field [5]. Systematic reviews [7, 8] of
previous studies addressing the subject have found insuf-
ficient evidence of associations between radiographic
grade of arthritis [9, 10] or clinical evidence of
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inflammation [10, 11] and response to IACI. One poten-
tially relevant, but so far insufficiently investigated factor
that may plausibly govern response to IACI is accuracy
of the injection. While the knee joint is perceived as
being easy to inject with a high degree of accuracy, up to
a third of routine injections based on anatomical land-
marks may fail to enter the joint cavity [12, 13]; it
remains unclear whether localisation of the steroid injec-
tion to within the knee joint cavity influences outcome.
The aim of this study was to determine whether accur-
acy of intra-articular placement of the injection, assessed
by ultrasound, associates with improved outcome in
terms of pain relief following routine IACI, based on
clinical landmarks, in knee osteoarthritis.
Methods
Subjects
This was a prospective observational cohort study of a
series of subjects with symptomatic knee OA who had
been recommended by their treating physician to have
an intra-articular steroid injection as part of their
routine care. The setting was a single teaching district
general hospital in the West Midlands of the UK. Poten-
tial participants were identified from orthopaedic and
rheumatology clinics based in the hospital.
Men and women were eligible if they satisfied the fol-
lowing criteria: i) aged 40 years and over, ii) evidence of
osteoarthritis of the knee according to ACR criteria [14],
iii) baseline pain of 100/500 mm or higher on the Western
Ontario and McMaster Universities Osteoarthritis Index,
version 3 (WOMAC) pain subscale [15], and iv) symp-
toms judged by the referring clinician as meriting IACI.
Subjects were excluded if they had received an intra-
articular or intramuscular steroid injection within the
preceding twelve weeks or were taking oral prednisolone
at a dose of 7.5 mg or higher or, a had a diagnosis of fibro-
myalgia or complex widespread pain, active RA or other
inflammatory arthritis
Baseline assessment
Subjects who consented to the study underwent baseline
assessment, immediately prior to treatment. They
completed an interviewer-assisted questionnaire which
included information about their age, past medical
history and whether or not they had received previous
knee injection. They also completed the WOMAC ques-
tionnaire [15]. This uses five 100 mm visual analogue
scales (VAS) to assess knee pain and produces scores
with a potential range of 0-500, with higher scores
denoting higher levels of pain. Height and weight were
assessed in a standard fashion. The baseline assessment
also included psychological scales, the details of which
will be reported in a separate manuscript. Subjects had
radiographs (antero-posterior, lateral and patellofemoral
‘skyline’ views) of their index knee unless already per-
formed within the previous 6 months. High-sensitivity
CRP (hsCRP) was measured using an enzyme immuno-
assay (MP Biomedicals, Solon, Ohio, US).
Radiographs were graded by agreement by two ob-
servers (GH and RK), blinded to clinical details, using a
standard atlas [16] which allows grading from 0 to 3 [0,
normal; 3, severe changes] for individual features of
osteophyte and joint space narrowing at both the tibiofe-
moral and patellofemoral joint (PFJ) including skyline
views of the patellofemoral joint. In this grading system,
which has been validated previously [17], grade 1 osteo-
phyte is considered equivalent to Kellgren-Lawrence
grade 2 [16]. The highest grade for each feature at any
site was used for further analysis. In addition, subjects
underwent ultrasound assessment with a 5–13 MHz
linear US probe (VF13-5; Antares, Siemens Healthcare
Diagnostics, Camberley, Surrey, UK) prior to injection
for synovial effusion thickness and semi-quantative syn-
ovial power Doppler signal estimation as described pre-
viously [18, 19]. All ultrasound procedures in the study
were performed by GH, a rheumatologist trained and
with two years’ experience in MSK US [18].
Intervention
The intervention was performed by one of several clinicians
who were not involved with any of the other study proce-
dures, including ultrasound. Using their usual preferred
anatomical approach and injection technique and under
guidance of clinical examination and landmarks only, the
clinician positioned the patient and they aspirated and
injected the joint under aseptic precautions with a 21 G
needle and a standard mixture of 40 mg triamcinolone
acetonide, 4 ml 1% lignocaine and 2 ml atmospheric air.
Assessment of accuracy of intra-articular placement of
injection
While the independent clinician performed the injection,
the sonographer placed the US probe over the knee joint
during the injection to determine placement of the injec-
tion. Blinding was maintained: the study subject and
injecting clinician were not informed about the US find-
ings. Air provides an effective US contrast medium
through its features of being strongly hyperechoic, exhi-
biting posterior acoustic shadowing, buoyancy and mo-
bility in fluid. We defined an accurate injection by the
presence of a positive air arthrosonogram (see Fig. 1),
i.e. the presence of any mobile air visible within the joint
cavity at the supra-patellar pouch. The technique was
adapted from Qvistgaard et al [20] and applied as
follows: at the time of injection, the US probe was
applied by GH to the midline suprapatellar pouch in the
transverse plane and a video clip recorded. Immediately
after the injection, a systematic US of all suprapatellar
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pouch areas was performed, starting at the site of injection
in order to identify a positive air-arthrosonogram.
Representative video clips were recorded, as was the
sonographer’s immediate impression of whether air-
arthrosonogram was present. A positive air-arthrosonogram
at any of these sites was used for further analysis. Following
intervention, participants were advised to rest the joint as
much as possible for 24 h, in line with normal departmental
practice.
Assessment of response
Participants completed the WOMAC pain subscale in
clinic at three weeks post injection and again at nine
weeks by postal questionnaire. We classified participants
as responders at each time point, if their pain scores
reduced by 40% or more from baseline, which has been
estimated both a clinically important and perceptible
change following intervention in knee OA [21].
Analysis
Descriptive statistics were used to summarise the subject
characteristics. We determined at both 3 and 9 weeks
whether subjects were responders or non-responders. We
looked for differences in subject characteristics by re-
sponse status at 3 and 9 weeks using t-tests for continuous
data and either Fisher’s exact test/Chi-Squared tests for
categorical data. Where subjects had omitted individual
WOMAC questionnaire items, these were replaced with
mean values for the relevant subscale, as far as was per-
mitted according to the manual. Factors considered as
potential confounders for adjustment in a multivariable
analysis included included gender, baseline pain, radio-
graphic grade, previous injection, body mass index. Inter-
observer reliability of the air-arthrosonogram technique
was calculated by presenting a sample of 26 stored video
clips from the study to three observers (GH, AS, RK; the
latter being a consultant radiologist and rheumatologist,
respectively, with over ten years experience in musculo-
skeletal ultrasound each. An equal number of clips were
selected from each set of originally classified as positive or
negative air arthrograms, respectively, at random. The
studies were viewed in random order, independently, by
the observers, who then scoring each as showing either
positive or negative air-arthrosonogram. Inter-observer
agreement was calculated for each pair of observers as a
kappa values and the mean value calculated for the three




A total of 105 patients were recruited to the study (Table 1).
Their mean age was 63.1 years and 62 (59%) were female.
Mean Body Mass Index (BMI) was 30.8 kg/m2. Baseline
pain level was 266 (SD 95.5)/500 mm. 104 subjects contrib-
uted outcome data at three weeks and 94 (89.5%) at nine
weeks. One participant submitted incomplete WOMAC
pain scores at 3 weeks. Of the 11 participants who did not
contribute to outcome data at nine weeks, one was with-
drawn due to an intercurrent episode of crystal arthritis,
one questionnaire was lost in the post and 9 failed to return
questionnaires. Those who failed to provide data at nine
weeks were younger, more likely to be male and had higher
CRP values than those providing full data, but there was no
difference in accuracy of injections and response rate at
3 weeks between these two groups (see Table 2).
Accuracy of injection
Mean inter-observer agreement for air-arthrosonogram
status was good, with mean kappa value between three
Fig. 1 A transverse ultrasound section of the mid supra-patellar pouch area of the right knee during the very early (a) and later (b) phase of injection,
showing a positive air arthrosonogram. There is an emerging area of intra-articular air bubbles (arrows), initially faintly (a) and then more clearly visible
(b), with posterior acoustic shadowing (*). Varying transducer pressure demonstrated the echogenic layer to be displaceable and display buoyancy,
consistent with intra-articular placement of the injection. SPP denotes suprapatellar pouch
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raters of 0.79. 98 (69.5%) injections were considered to
be accurate as determined by the presence of air on the
arthrosonogram at the time of injection.
Predictors of response
The overall positive response rate was 61% at three
weeks and 46% at nine weeks. A positive arthrosono-
gram did not predict responder status at 3 or 9 weeks;
in fact at both time points, response rates were higher in
those with negative than those with positive arthrosono-
gram (e.g. 75% vs 64%, p = 0.365 at nine weeks) (Table 3),
although these results were not statistically significant.
There were no statistically significant differences in base-
line clinical, radiographic, sonographic and serological
characteristics between responders and non-responders
with two exceptions: Female gender associated with re-
sponse at three weeks (p = 0.045) and previous injection
with non-response at nine weeks (p = 0.021) (Table 3).
A post-hoc analysis of absolute change in pain scores
from baseline in groups with positive vs negative arthro-
sonogram showed no difference: -114.0 vs -123.4. mm,
p 0.724 at three weeks; and -58.8 vs -96.5 mm, p 0.185 at
nine weeks (data not shown in table).
Discussion
In this prospective observational study we have shown
that in knee osteoarthritis accurate intra-articular place-
ment of a corticosteroid injection, as determined by
positive air-arthrosonogram, did not improve the rate of
clinically significant response or mean pain reduction at
three or nine weeks post injection, compared to a group
in whom a negative arthrosonogram suggested that
placement of injection was predominantly extra-
articular. A recent systematic review [13] found that on
average only 77% of knee injections enter accurately the
intra-articular cavity when using clinical landmarks as
guidance for injection. It is therefore plausible to assume
that accuracy of injection may potentially explain the
variability of response to IACI in knee OA. While there
is little doubt that guidance by US improves accuracy of
intra-articular placement of injection, there remains un-
certainty, however, as to how whether this affects out-
come [13]. In a small randomized placebo-controlled
study of 38 patients with knee OA, Sambrook et al
found no difference in outcome between intentional
intra-articular vs peri-patellar injection of methylpredni-
slone between one and 12 weeks post injection. This
remains the only study that we are aware of that used
clinical guidance of injection to address the role of intra-
vs extra-articular corticosteroid injection in knee OA on
outcome. The fact that no difference was observed in
that study may have been due to the fact that correct
intra-articular placement was not verified by further
imaging (i.e. some intended intra-articular injections
may still have ended up extra-articularly) and/or lack of
power (i.e. insufficient study sample) to show a differ-
ence. Sibbitt et al [22] examined the effect of ultrasound
(US)-guidance vs clinically guided IACI in a randomised
study of 94 subjects with knee OA. No information on
accuracy of the injection with either method is provided,
but subjects undergoing US-guided injection were
approximately twice as likely to have a positive response
at 2 weeks (defined as a pain VAS of < 2 cm). A second
Table 1 Baseline characteristics and responder status of study
population
Characteristics n = 105
Age [years] [mean (SD)] 63.1 (11.3)
Female [n (%)] 62 (59%)
BMI [mean (SD)] 30.8 (5.5)
Previous injection [n (%)] 60 (57%)
Baseline WOMAC Pain [mean(SD)] 266 (95.5)
US effusion depth [mm] [Mean (SD)] 3.74 (2.27)
PD grade [median (IQR)] 0 (0,1)
Osteophyte grade [median (IQR)] 2 (1, 3)
JSN grade [median (IQR)] 2 (1,2)
hs CRP [mg/L] [median (IQR)] 4.4 (1.7,7.1)
Positive US arthrogram [n (%)] 74 (70.5%)
Responders at 3 weeks [n (%)] 63 (60.6%)
Responder at 9 weeks [n (%)] 43 (45.7%)
Abbreviations: BMI body mass index, PD power Doppler, JSN joint space
narrowing, hsCRP high-sensitivity CRP, US ultrasound
Table 2 Characteristics of subjects completing the study compared
with those who failed to complete the study






Age [years] [mean (SD)] 64.3 (11.4) 57.1 (8.3) 0.043
Female [n (%)] 59 (62.8%) 3 (27.3%) 0.047
BMI [mean(SD)] 30.7 (5.3) 31.7 (7.5) 0.549
Previous injection [n (%)] 56 (59.6%) 4 (36.4%) 0.199
Baseline Pain [mean (SD)] 264.5 (97.1) 275.4 (84.3) 0.724
US effusion depth [mm]
[mean (SD)]
3.7 (2.3) 3.8 (1.7) 0.924
PD grade [median (IQR)] 0 (0,1) 0 (0,1) 0.702
Osteophyte grade
[median (IQR)]
2 (1,3) 2 (1,3) 0.977
JSN grade [median (IQR)] 2 (1,2) 2 (1,2) 0.538
hsCRP [mg/L]
[median (IQR)]
5.58 (1.5,6.5) 7.80 (3.8, 10.1) 0.021
Positive US arthrogram
[n (%)]
66 (70.2%) 8 (72.7%) 1.00
Responder at 3 weeks
[n (%)]
56 (60.2) 7 (63.6) 1.00
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smaller study of essentially similar design by the same
group showed similar findings. Both studies have not
tried to control for any treatment effect likely to be con-
ferred by the use of ultrasound itself, in other words:
having an injection under ultrasound than without may
have significant beneficial effect per se without any rela-
tionship to improved accuracy. That this is likely to be
relevant is suggested by work by Cunnington et al [23]
who used sham-US to compare US-guided injection vs
clinically-guided injections in a variety of joints in a
large study of 184 subjects with inflammatory arthritis:
whilst, as expected US-guided injections were more
accurate than clinically guided with sham-US, there was
no difference in outcome (both pain and function) be-
tween the two groups. Furthermore, and more relevant
to this study, function (but not pain) at six (but not two)
weeks was the only parameter that showed positive
correlation with accuracy of injection. A trial studying
US-guided vs ‘sham-US’ clinically-guided injection has
been terminated and is to date unreported (ClinicalTrials.gov
Identifier: NCT01032720; accessed 15 June 2015).
We chose outcome assessment at three and nine
weeks, as these time points reflect the period during
which benefit of treatment has been suggested in previ-
ous systematic reviews of placebo-controlled trials [5, 6].
Our study showed further interesting observations:
participants who had previous experience of injection
were less likely to report response to treatment than
those undergoing their first injection at nine weeks
(p 0.021), but not three weeks. This seems to concur
with the anecdotal clinical observation that the effect
of subsequent IACI in knee OA is less than of first
injections. In line with most [11, 24–26], but not all
studies [9, 10], we found no association between
radiographic severity and rate of response, despite
scoring separately for individual features of knee
osteoarthritis. In accordance with other investigators
[27, 28], we found no relationship between response
and sonographic effusion or synovial power Doppler,
despite using a sonographic assessment that included
measures from the medial, mid and lateral aspect of the
supra-patellar pouch rather than single view data.
The main strength of our study is that it was based on
routine practice of IACI, using clinical guidance and
subjects referred for IACI by their clinician as part of
routine clinical management. As such we believe the
results are applicable to a general population. However,
we have seen a better response rates than placebo-
controlled studies [5] probably due to contextual, non-
specific treatment effects. Conversely, in trying to reflect
a ‘real-world’ treatment environment, we did not limit
the use of other interventions including analgesics, walk-
ing sticks and physiotherapy, which could have affected
patient outcomes.
This study has a number of limitations: As an observa-
tional study, it remains possible that an adequately
powered, placebo-controlled trial might disclose an
effect of accuracy of injection on outcome. We did not
perform a formal power calculation based on arthrogram
status for this observational trial and one could argue
that our sample size is too small to show an effect of ac-
curacy or other structural factors on outcome However,
the reported rate of response was numerically higher in
those with a negative air-arthrosonogram at both three
and nine weeks, suggesting that a larger sample would
be unlikely to show superiority of response rate in those
with a positive vs those with a negative arthrogram. We
did not use a second imaging method (e.g. MRI or
limited CT) to validate our method to verify accurate
intra-articular injection as previously described by
Qvistgaard et al [20]. We therefore acknowledge that there
are limitations in the air-arthrosonogram technique as an
Table 3 Baseline characteristics of responders vs non-responders (n = 105)
3 weeks (n = 104) 9 weeks (n = 94)
Characteristics Responder (n = 63) Non-responder (n = 41) P Responders (n = 43) Non-Responder (n = 51) P
Age [years] [mean (SD)] 64.4(10.6) 61.8(11.9) 0.258 64.1(11) 64.5(11) 0.890
Female [n (%)] 42 (67%) 19 (46%) 0.045 31 (72%) 28 (55%) 0.093
BMI [mean(SD)] 31.3(5.4) 30.0(5.8) 0.265 30.9(4.8) 30.4(5.8) 0.658
Previous injection [n (%)] 33 (52%) 26 (63%) 0.314 20 (47%) 36 (71%) 0.021
Baseline Pain [mean (SD)] 256(87) 279(107) 0.240 243(91) 282(99) 0.057
US effusion depth [mm] [mean (SD)] 3.57(2.1) 4.07(2.6) 0.280 3.29(1.9) 4.14(2.59) 0.080
PD grade [median (IQR)] 0(0,1) 0(0,1) 0.790 0(0,1) 0(0,1) 0.376
Osteophyte grade [median (IQR)] 2(1,3) 2(1,3) 0.870 2(1,2) 2(1,3) 0.540
JSN grade [median (IQR)] 2(1,2) 2(1,2) 0.796 2(1,2) 2(1,2) 0.461
hsCRP [mg/L] [median (IQR)] 3.5(1.5,6.8) 4.6(2.2,8.6) 0.147 3.0(1.5,5.7) 4.5(1.7,8.6) 0.857
Positive US arthrogram [n (%)] 42 (67%) 30 (73%) 0.389 27 (64%) 38 (75%) 0.365
See legend to Table 1 for abbreviations
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indicator of intra- vs extra-articular placement of injec-
tion, even though our interobserver reliability was good.
Our accuracy data on the basis of the air-arthrosonogram
method of 70% are also broadly in line with those reported
in a recent systematic review [13]. We therefore do not
believe that the technique resulted in significant systemic
misclassification.
Beyond the question of relevance of precise intra- vs
extra-knee joint cavity placement, the question remains
as to whether an injection close to the synovium (e.g.
the fat-pad of the knee) can be shown to be of equivalent
effectiveness on outcome. Our study suggests this possi-
bility, but due to its lack of precise visualisation of injec-
tate localisation in those with a negative arthrosonogram,
we are unable to draw any firm conclusions on this possi-
bility. Our findings suggest that accurate intra-articular
injection is neither a guarantor nor a pre-requisite of
response at 3 and 9 weeks and provides support the
current practice of IACI in knee OA using clinical land-
marks and palpation. Whilst US may well have a treat-
ment effect of its own and recognised to be useful to assist
for aspiration or technically difficult injections, there is to
date no convincing indication that the improved accuracy
it confers to the injection matters to outcome of pain relief
in this setting.
Conclusion
Our ‘real-life’, observational study suggests that IACI
based on routine, clinically guided practice leads to relief
of knee pain in osteoarthritis in the short- and medium-
term in patients with uncertain placement of injection,
as well as those in whom injections could be demon-
strated to be in the intra-articular space. This casts
doubt over the relevance of accuracy of intra-articular
injection placement to clinical outcome in this setting.
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